Clinical Trials

Clinical Trial Detail

Return to search results.

MRI and PET Imaging in Predicting Treatment Response in Patients With Stage IB-IVA Cervical Cancer

Complete title: MRI- and PET-Predictive-Assay of Treatment Outcome in Cancer of the Cervix

Research Study Number       8118
    
Principal Investigator       Nina Mayr, MD
    
Phase       NA

Look up trial at NIH

Research Study Description

This clinical trial studies magnetic resonance imaging (MRI) and positron emission tomography (PET) imaging in predictive treatment response in patients with stage IB-IVA cervical cancer. MRI is a procedure in which radio waves and a powerful magnet linked to a computer are used to create detailed pictures of areas inside the body. PET is a procedure in which a small amount of radioactive glucose (sugar) is injected into a vein, and a scanner is used to make detailed, computerized pictures of areas inside the body where the glucose is taken up. Comparing results of diagnostic procedures, such as MRI and PET, done before, during and after radiation and chemotherapy may help doctors predict a patient's response to treatment and help plan the best treatment.

Eligibility Criteria (must meet the following to participate in this study)

Ages Eligible for Study: 18 Years and older

Genders Eligible for Study: Female

- Patients must have histologically confirmed stage IB2-IVA epithelial carcinoma of the cervix, including squamous cell, adeno-, and undifferentiated carcinoma, and excluding small cell/neuroendocrine carcinoma, who will undergo radiation therapy for cervical cancer with curative intent

- Surgical staging with retroperitoneal staging and lymphadenectomy is permitted

- Patients who will undergo standard radiation therapy with concurrent cisplatin-based chemotherapy for cervical cancer

- Patients with no prior radiation therapy to the pelvis

- Patients with no contra-indications to magnetic resonance (MR) imaging as stated in the section exclusion criteria

- Patients must have adequate renal function: glomerular filtration rate (GFR) >30 mL/min/1.73 m^2; for the test-retest sub-study MRI, patients must have a GFR of > 60 mL/min/1.73m^2

- Ability to understand and the willingness to sign a written informed consent document

Other eligibility criteria may apply.

Exclusions (conditions that would prevent participation in this study)

- Patients with small cell/neuroendocrine cervical carcinoma

- Patients who have received any prior pelvic radiation therapy in the area of the tumor that precludes the delivery of a curative dose of pelvic radiation

- Medical contraindication to MR imaging (e.g. pacemakers, metallic implants, aneurysm clips, known contrast allergy to gadolinium contrast, pregnancy, nursing mothers, weight greater than 350 pounds, GFR < 30)

- Major medical or psychiatric illness that, in the investigator's opinion, would prevent completion of treatment, completion of the study protocol, or interfere with follow-up

- Life expectancy of less than 6 months

Other exclusion criteria may apply.



Research Study Number       8118
    
Contact       Mimi Lee
    
Telephone       206/598-4110
    
   

Keywords
Cervical Cancer; Gynecological Cancer; Solid Tumors; Uterine Cancer

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials